Sprint Bioscience initiates marketing of an additional cancer drug program
Sprint Bioscience announces today that it is starting to market the DISA program to potential partners and, following a series of research advances, reveals the cancer drug program's target protein, TREX1. The goal of the program, currently in the preclinical phase, is to develop drugs that inhibit the protein TREX1 in order to enhance the effect of immuno-oncological therapy, radiation therapy and chemotherapy in the treatment of cancer. The company will initiate discussions with potential partners in connection with the BioEurope conference in October.Cancer cells often have elevated